Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Disc Medicine, Inc. (NASDAQ:IRON)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,391 shares of the company’s stock, valued at approximately $317,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of Disc Medicine by 358.7% during the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock worth $118,320,000 after buying an additional 1,459,434 shares during the period. Janus Henderson Group PLC lifted its position in Disc Medicine by 62.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after acquiring an additional 467,988 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Disc Medicine by 23.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock valued at $88,421,000 after acquiring an additional 262,690 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $5,579,000. Finally, Renaissance Technologies LLC bought a new position in shares of Disc Medicine in the fourth quarter worth about $5,479,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Morgan Stanley initiated coverage on Disc Medicine in a research note on Thursday, July 3rd. They set an “overweight” rating and a $85.00 target price for the company. Raymond James Financial started coverage on Disc Medicine in a research report on Wednesday, June 11th. They issued a “strong-buy” rating and a $89.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research report on Thursday, July 3rd. BMO Capital Markets increased their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, May 12th. Finally, Truist Financial assumed coverage on shares of Disc Medicine in a research report on Monday, July 21st. They issued a “buy” rating and a $86.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $95.73.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $58.97 on Monday. The firm has a market capitalization of $2.04 billion, a PE ratio of -15.04 and a beta of 0.77. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $68.73. The firm has a 50-day moving average price of $53.75 and a 200 day moving average price of $51.34.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.03). Research analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Kevin Bitterman sold 29,837 shares of the business’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $60.97, for a total value of $1,819,161.89. Following the sale, the director owned 647,002 shares in the company, valued at approximately $39,447,711.94. The trade was a 4.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jean M. Franchi sold 2,031 shares of the stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $59.00, for a total transaction of $119,829.00. Following the sale, the chief financial officer owned 63,499 shares of the company’s stock, valued at $3,746,441. This trade represents a 3.10% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,730 shares of company stock valued at $6,210,551. 4.24% of the stock is owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.